×

RNS Number : 4584F

Osirium Technologies PLC

21 February 2018

 

For immediate release

21 February 2018

 

Osirium Technologies plc

 

("Osirium" or "Group")

 

Contract win with a Global Online Retailer

 

 

Osirium Technologies plc (AIM: OSI.L), a UK headquartered cyber-security SaaS provider, is pleased to announce a contract win with a global online fashion retailer.

 

The Group has appointed Osirium to deliver its full PxM product offering of Privileged Account Management, Privileged Task Management, Privileged Session Management modules and associated consultancy services, supporting over 1,000 servers. 

 

David Guyatt, Chief Executive Officer, commented: "We are delighted to have won a contract with a prestigious global online fashion retailer. The development is significant for Osirium as we continue to play a crucial role in providing solutions that protect companies from future cyber-attacks.  Osirium looks forward to working closely with the Group and we pride ourselves in offering a trusted and reliable service."

– Ends –

For further information:

Osirium Technologies plc	Tel: +44 (0) 118 324 2444
David Guyatt, Chief Executive Officer Rupert Hutton, Chief Financial Officer www.osirium.com
Stifel Nicolaus Europe Limited (Nominated Adviser and Broker)	Tel: +44 (0) 20 7710 7600
Fred Walsh / Neil Shah / Ben Maddison
Yellow Jersey PR (Financial PR) Sarah Hollins	Tel: +44 (0) 7764 947137

 

Notes to Editors:

 

About Osirium

Osirium Technologies plc (AIM: OSI.L), is a UK headquartered cyber-security Software-as-a-Service ("SaaS") provider. Osirium protects critical IT assets, infrastructure and devices by preventing targeted cyber-attacks from directly accessing Privileged Accounts, removing unnecessary access and powers of Privileged Account users, deterring legitimate Privileged Account users from abusing their roles and containing the effects of a breach if one does happen.

 

Osirium has defined and delivered what the Directors view as the next generation PAM (Privileged Access Management) solution.  The team has developed the concept of Virtual Air Gap to separate users from passwords, with Osirium's Privileged Task Management module further strengthening Privileged Account security and delivering impressive return on investment benefits for customers.

Founded in 2008 and with its headquarters in Reading, UK, the Group was admitted to AIM in April 2016.  For further information please visit www.osirium.com

 

 

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

CNTFKKDPDBKBNBB

Close

×

RNS Number : 3282F

Concepta PLC

20 February 2018

 

20 February 2018

 

Concepta plc

("Concepta" or the "Company")

 

Launch of myLotus app in China

 

Concepta plc (AIM: CPT), the UK healthcare company and developer of a proprietary product targeted at the mobile health market with a primary focus on women's fertility, is pleased to announce that it has signed an agreement with Beijing Jiayou Ltd, ("AppInChina") to manage the distribution of its new myLotus app on Android systems throughout China.

 

The free app, which allows women to monitor and track fertility, can be used either as an individual fertility tracker or in conjunction with the myLotus monitor.

 

Through AppInChina, Concepta will focus on distribution of the app through the top 5 Chinese Android app stores, which between them have a market share of around 75.7%* of the Android app market. This includes Tencent's Myapp, the leading Chinese app store, which holds a 25.1%* market share of the Android app distribution coverage in China.

 

In addition, the myLotus app is also currently available on the Chinese iOS app store, which has a 13% smartphone market share in China.

 

Erik Henau, CEO of Concepta commented: "The myLotus app is an extremely useful resource for women trying to conceive. Not only is it effective as a stand-alone resource, but in conjunction with our myLotus meter, it is a powerful tool to allow women with unexplained infertility to conceive naturally. It enables women who are struggling to conceive to monitor their ovulation cycle more effectively than standard home testing kits. The combination of both the app and the myLotus meter will enhance the consumer experience and the product proposition, as well as increasing awareness of the product."

 

"As the only app with a direct link to qualitative and quantitative results of a woman's personal hormone levels, it provides women with a platform to build an accurate conception diary, which will assist them and their partner during the process of conception."

 

* Newzoo – "Top 10 android app stores" https://newzoo.com/insights/rankings/top-10-android-app-stores-china/ 

 

Enquiries:

The Company

Erik Henau

CEO

Tel: +44 (0) 1234 866601

 

SPARK Advisory Partners Limited (Nomad)

Neil Baldwin / Mark Brady

Tel: +44 (0)20 368 3550

 

NOVUM Securities Limited (Broker)

Colin Rowbury

+44 (0) 20 7399 9400

 

Yellow Jersey (Financial PR)

Georgia Colkin / Joe Burgess / Katie Bairsto

Tel: +44 (0) 776 932 5254

 

About Concepta Plc:

Concepta plc is an AIM-quoted pioneering UK healthcare company that has developed a proprietary product, myLotus, targeted at the personalised mobile health market with a primary focus on unexplained infertility* in women.

 

myLotus is currently the only consumer product which allows both quantitative and qualitative measurements of a woman's personal LH and hCG* hormone levels in a home test, facilitating higher conception rates and early diagnosis of issues with fertility hormones. The proposition of myLotus is to help women conceive naturally.

Concepta has made significant progress recently, establishing agreements with a number of distributors in China where myLotus has been given cFDA approval. Concepta is initially targeting the traditional route to market in China through Chinese hospitals and plans to add the direct-to-consumer route in the near future.

 

The Company is also well on its way to achieving CE-marking and commencing its direct-to-consumer launch in the UK and Europe in H1 2018. The Company has identified a significant global market opportunity, with revenue potential of the Chinese and EU unexplained infertility market estimated to be worth c.£600m per annum.

 

*Unexplained infertility refers to women that have been unable to conceive after 6 months of trying. This highly motivated target group of consumers won't typically be offered medical intervention until 12 months of unsuccessfully trying, with IVF not offered until two years. Research indicates couples start to take positive action ahead of this time and there is little medical support to help them do so.

 

About RNS Reach announcements

RNS Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases such as marketing messages, corporate and product information into the public domain. An RNS Regulatory announcement is required to be notified under the AIM Rules for Companies.

 

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

NRAFKCDBDBKBCBD

Close

×

RNS Number : 3219F

First Derivatives PLC

20 February 2018

 

20 February 2018

 

First Derivatives plc

("FD" or the "Group")

 

Contract Win in Gaming

 

FD (AIM:FDP.L, ESM:FDP.I) announces that it has signed a contract with a FTSE 100 gaming company for the use of Kx technology to provide data analytics services. The contract win follows a successful proof of concept in which Kx provided operational intelligence that demonstrated a compelling return on investment versus traditional database solutions and open source alternatives. The customer is one of the world's leading sports betting and gaming operators with over four million customers globally and processes billions of transactions per day.

 

According to industry analysts Global Markets Insights, the retail analytics markets will surpass $13 billion by 2024. In attacking these markets, Kx will target potential customers including gaming, retail and airline and e-Commerce giants to address opportunities around customer yield, customer churn and pricing analysis.

 

Brian Conlon, Chief Executive Officer of Kx, commented: "This contract win is a powerful endorsement of our technology and we are very excited to work in partnership with this leading gaming company to help them to develop real-time insights across their activities. This win further demonstrates the flexibility of our horizontal technology which is being used across many industries in a variety of areas such as real-time analytics, Industrial IoT, cybersecurity and Artificial Intelligence."

 

 

Enquiries

For further information please contact:

First Derivatives plc Brian Conlon, Chief Executive Officer Graham Ferguson, Chief Financial Officer Ian Mitchell, Head of Investor Relations	+44(0)28 3025 2242 www.firstderivatives.com
Investec Bank plc (Nominated Adviser and Broker) Andrew Pinder Carlton Nelson Sebastian Lawrence	+44 (0)20 7597 5970
Goodbody (ESM Adviser and Broker) Linda Hickey Finbarr Griffin	+353 1 667 0420
FTI Consulting Matt Dixon Dwight Burden Darius Alexander Niamh Fogarty	+44 (0)20 3727 1000

About FD

FD is a global technology provider with 20 years of experience working with some of the world's largest finance, technology, retail, pharma, manufacturing and energy institutions. The Group's Kx technology, incorporating the kdb+ time-series database, is a leader in high-performance, in-memory computing, streaming analytics and operational intelligence. Kx delivers the best possible performance and flexibility for high-volume, data-intensive analytics and applications across multiple industries. FD operates from 14 offices across Europe, North America and Asia Pacific, including its headquarters in Newry, and employs more than 2,000 people worldwide.

 

For further information, please visit www.firstderivatives.com and www.kx.com

 

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

NRAEAXANFSSPEFF

Close

×

RNS Number : 2390F

SpaceandPeople PLC

19 February 2018

 

The information contained within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014. Upon the publication of this announcement, this inside information is now considered to be in the public domain.

SpaceandPeople plc

("SpaceandPeople" or the "Group")

Contract Renewal and Expansion

SpaceandPeople plc (AIM:SAL) is pleased to announce a contract renewal and significant expansion of opportunities with Landsec in the UK.

Landsec owns and operates 15 shopping centres and 33 retail and leisure parks in the UK and is one of SpaceandPeople's largest clients. The new agreement is a five-year contract to provide revenues from experiential activity, pop up retail and mobile promotion kiosks ("New Agreement").

The New Agreement extends across their portfolio of shopping centres including, for the first time, Southside Wandsworth and the newly relaunched Westgate Oxford. In addition, the New Agreement includes Landsec's retail and leisure parks, their three recently acquired outlet centres as well as their Central London business estate.

Mark Warne, Head of Commercial Partnerships at Landsec, said: "Working with SpaceandPeople enables Landsec to offer our customers the best brand experiences, promotions and services across our retail, leisure and office portfolio. We look forward to continuing to work with SpaceandPeople and their team."

Matthew Bending, Group CEO of SpaceandPeople said: "I am delighted that we are continuing and developing our relationship with Landsec, one of the UK's largest real estate investors. We work closely with the Landsec team to ensure that we are providing market leading brand promotions and attractive and relevant pop up retail and promotional solutions. The Landsec estate represents the right mix of dominant and convenient assets with an emphasis on experience and we look forward to growing our business with them even further over the coming years."

Ends

Contact details:

 

SpaceandPeople Plc	0845 241 8215
Matthew Bending, Gregor Dunlay
Cantor Fitzgerald Europe	020 7894 7000
David Foreman, Will Goode (Corporate Finance)
Alexander Pollen (Sales)

 

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

CNTGGUPAPUPRUMB

Close

×

RNS Number : 9380E

Concepta PLC

15 February 2018

 

15 February 2018

Concepta plc

("Concepta" or the "Company")

Concepta signs contract in China to support marketing of myLotus in Chinese hospitals

 

Concepta plc (AIM: CPT), the UK healthcare company and developer of a proprietary product targeted at the mobile health market with a primary focus on women's fertility, is pleased to announce that it has signed a marketing agreement with Wei Yi Bei Lian (Shanghai) Information Technology Co., Ltd ("BB Link").

BB Link offers free WiFi to waiting rooms in 1,500 maternity hospitals across China. Concepta has developed a landing page that will be displayed when patients connect to this WiFi service. The page will give an overview of the myLotus product and a link to the Concepta website where more in depth information can be found. Initially, Concepta's landing page will be launched in a select number of hospitals, and longer term, the Company will be able to reach hundreds of thousands of women in a phased rollout, through a highly targeted marketing channel.

Concepta's distributors will also train the doctors at these hospitals on the myLotus product, enabling them to provide further detailed information and recommendations to patients that could benefit from its use.

Erik Henau, CEO says: "Co-operation with BB Link allows us to target the most relevant potential users of myLotus in a cost-effective way. Additionally, if women are able to read about the product prior to seeing the doctor, there is a greater scope for market penetration.

"BB Link has developed a sophisticated platform with metrics that permit the measurement of campaign success. We will start with a trial that will help us to refine our key messages to our consumers and to learn how the information links to the logistics of the hospital route.

"This is an important step in building our consumer brand in China and in working with the hospital route to market."

Enquiries:

The Company

Erik Henau

CEO

Tel: +44 (0) 1234 866601

 

SPARK Advisory Partners Limited (Nomad)

Neil Baldwin / Mark Brady

Tel: +44 (0)20 368 355

 

NOVUM Securities Limited (Broker)

Colin Rowbury

+44 (0) 20 7399 9400

 

Yellow Jersey (Financial PR)

Georgia Colkin / Joe Burgess / Katie Bairsto

Tel: +44 (0) 776 932 5254

 

About Concepta Plc:

Concepta plc is an AIM-quoted pioneering UK healthcare company that has developed a proprietary product, myLotus, targeted at the personalised mobile health market with a primary focus on unexplained infertility* in women.

myLotus is currently the only consumer product which allows both quantitative and qualitative measurements of a woman's personal LH**and hCG***hormone levels in a home test, facilitating higher conception rates and early diagnosis of issues with fertility hormones. The proposition of myLotus is to help women conceive naturally.

Concepta has made significant progress recently, establishing agreements with a number of distributors in China where myLotus has been given cFDA approval. Concepta is initially targeting the traditional route to market in China through Chinese hospitals and plans to add the direct-to-consumer route in the near future.

The Company is also well on its way to achieving CE-marking and commencing its direct-to-consumer launch in the UK and Europe in H1 2018. The Company has identified a significant global market opportunity, with revenue potential of the Chinese and EU unexplained infertility market estimated to be worth c.£600m per annum.

*Unexplained infertility refers to women that have been unable to conceive after 6 months of trying. This highly motivated target group of consumers won't typically be offered medical intervention until 12 months of unsuccessfully trying, with IVF not offered until two years. Research indicates couples start to take positive action ahead of this time and there is little medical support to help them do so.

** LH: Luteinising hormone is produced by the pituitary gland and is one of the main hormones that control the reproductive system.

*** hCG: Human chorionic gonadotropin is a hormone produced by the placenta after implantation and is an indicator of pregnancy.

 

About RNS Reach announcements

RNS Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases such as marketing messages, corporate and product information into the public domain. An RNS Regulatory announcement is required to be notified under the AIM Rules for Companies.

 

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

NRALFFFFFEISLIT

Close

×

RNS Number : 5106E

YouGov PLC

12 February 2018

 

 

12 February 2018

YouGov plc

("YouGov" or "the Group")

 

New advertising platform YouGov Direct announced

YouGov Direct enables greater consumer data protection and effective ad targeting

YouGov, the international market research and data analytics group, today announces the development of a new digital advertising platform, YouGov Direct. Currently consumers have little control over their data, while ineffective targeting has a negative impact on brands and publishers. YouGov Direct aims to overcome those problems in the ad ecosystem by harnessing blockchain technology to verify the data exchange between consumers and advertisers.

Through YouGov Direct, panellists will be able to choose which personal attributes to make available to third parties while remaining anonymous. For example, a user might decide to share information about favourite hobbies and withhold data related to health history. In exchange for sharing their data, users will earn additional rewards.

Advertisers, brands and publishers using the platform gain access to known audience attributes, which enable more effective advertising targeting and better campaign performance. YouGov Direct's transparent and verifiable record of transactions provides assurance that ads are reaching actual humans as opposed to bots and will support businesses in meeting the requirements of the forthcoming EU General Data Protection Regulation (GDPR).

YouGov expects to launch the product to customers during the course of FY19.

To register your interest in YouGov Direct, go to direct.yougov.com.

 

Enquiries:

YouGov plc

Stephan Shakespeare / Alex McIntosh                  020 7012 6000

FTI Consulting (PR)

Charles Palmer / Harry Staight                                   020 3727 1000

Numis Securities (NOMAD and broker)

Nick Westlake / Toby Adcock                                     020 7260 1000

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

NRAUGUCWPUPRGMB

Close

×

RNS Number : 0957E

Malvern International PLC

07 February 2018

 

7 February 2018

MALVERN INTERNATIONAL PLC

("Malvern" or the "Company")

 

Launch of Malvern Online Academy

 

Malvern International plc (AIM: MLVN), provider of educational services in the UK, Europe and Asia, is pleased to announce the official launch of Malvern Online Academy ("MOA") which will provide online and live (real time) teaching and training sessions for existing and new students, including corporate trainees as well as members of the general public.  The sessions will be available in two formats:  real-time 'live' instructor-led sessions; and pre-recorded sessions which can be accessed at anytime.

 

MOA will aim to offer all courses and programmes currently being run in Malvern schools in London, Malaysia and Singapore.  The first programmes being offered through the online platform are the suite of English language courses currently taught in Malvern House London.  These will be available to students and schools in Asia, India, the Middle East, Europe and South America, all territories in which Malvern already has a market presence through educational institutions and agents.  Following on from the English classes, MOA's offering will be extended to include all its accounting and accountancy-related courses, with the ultimate aim of being able to offer all its existing courses including ones that are bespoke to suit the needs of various online customer groups.

 

Target markets will include alumni from all of Malvern's schools, as well as corporate entities and various organisations for which online professional development and training courses are well suited.

Commenting  Dr Sam Malafeh, Chief Executive Officer said " the global online market is expected to grow very significantly over the next decade. Building upon the creation of Malvern's digital learning and technology division in 2017, further development, innovation and expansion into the online market is a vital tenet of its strategic plan for 2018.  Malvern believes it is in an excellent position to capitalise strongly  on the current global demand for online learning by virtue of its existing span of high-quality programmes and offerings, the combined skills and expertise of its global teaching staff as well as its international network of partners, institutions and agents within the education industry."

For more information, please visit:

https://online.malverninternational.com 

Or: https://www.malverninternational.com/malvern-colleges/malvern-online-academy/

 

Contacts:
Malvern International plc	www.malverninternational.com
Haider Sithawalla Dr Sam Malafeh	+65 64120733 +65 83860155 / +447391035823
WH Ireland Limited	www.whirelandcb.com
Mike Coe, Ed Allsopp	+44 (0) 117 945 3470

 

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

MSCTFMATMBAMBPP

Close

×

RNS Number : 8042D

N4 Pharma PLC

02 February 2018

 

N4 Pharma Plc

("N4 Pharma" or the "Company")

Award of Grant

and

Collaboration with MedImmune UK

N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company which reformulates existing drugs and vaccines to improve their performance, announces that it has been awarded a feasibility grant from Innovate UK, the UK's innovation agency, to co-fund a collaborative project with MedImmune UK, a leading global biologics R&D company, to explore the manufacture of a prototype nanomedicine using N4 Pharma's Nuvec® system.

 

The grant is from Innovate UK's Medicines Manufacturing Round 1: Challenge Fund, which itself is funded through the UK Government's £70m Industrial Strategy Challenge Fund to speed up the development of new medicines, details of which were announced on 22 January 2018 by Sam Gyimah, MP, the Universities and Science Minister. The project with MedImmune is expected to last for approximately nine months from 1 February 2018.

The grant is to enable N4 Pharma to develop manufacturing methods for Nuvec® particles loaded with therapeutic pDNA/mRNA encoding antigens and to demonstrate that such nanoparticles can be manufactured to the quality required for in-vivo studies. MedImmune will then evaluate these Nuvec formulations in relevant in-vitro and in-vivo models to demonstrate if they are able to deliver functional pDNA/mRNA capable of inducing an immune response.

Under the terms of the collaboration agreement with the Company, MedImmune has the right at any time during the collaboration project, and 3 months following its conclusion, to give notice that it wishes to negotiate the terms on which N4 would grant it an exclusive licence to utilise the results of the evaluation.

Further information on each of MedImmune UK and Innovate UK is set out below.

Nigel Theobald, CEO of N4 Pharma, commented: "We are delighted to have been awarded the feasibility grant from Innovate UK and to have the opportunity to work with MedImmune UK on this collaborative project. We continue to make great progress with our Nuvec® particles and we believe that MedImmune is the ideal partner to evaluate our nanoparticles in this field."

Enquiries:

N4 Pharma Plc Nigel Theobald, CEO	Via Alma PR
Stockdale Securities Tom Griffiths	Tel: +44(0)207 601 6100
Beaufort Securities Elliot Hance	Tel: +44(0)207 382 8300
Alma PR Josh Royston Robyn Fisher	Tel: +44(0)778 090 1979 Tel: +44(0)754 070 6191

 

About N4 Pharma

 

N4 Pharma is a specialist pharmaceutical company which reformulates existing drugs and vaccines to improve their performance.

N4 Pharma's reformulation work falls under two divisions:

• generic, already commercialised, drugs; and

• delivery of novel and existing vaccines.

N4 Pharma has identified a number of established drugs that could be improved upon through its reformulation techniques. N4 Pharma's most advanced reformulation is for sildenafil, widely marketed as Viagra, where N4 Pharma is seeking to improve the speed at which the drug takes effect whilst also extending its duration of action.

N4 Pharma's reformulation approach should take approximately three years to obtain regulatory approval as opposed to the traditional process for new drugs of on average ten years. The cost and risk profile of this model is also significantly less than the traditional process. N4 Pharma's business model for generics is to take reformulated drugs from its portfolio through to the stage where it will license its newly reformulated drugs to pharmaceutical companies to commercialise them. N4 Pharma's revenues should be derived from up front milestone and royalty payments associated with the licence.

N4 Pharma's business model for vaccines is to undertake the required clinical work to demonstrate the capability of its delivery system as a cancer vaccine or therapeutic treatment so that it can license the technology to major players developing treatments in this area, again in return for up front milestone and royalty payments associated with the licence.

 

About MedImmune UK

 

MedImmune is part of Astra Zeneca, having been acquired in 2007 for $15.6bn. It is a leading global biologics R&D company with one of the largest, most robust pipelines in the industry, including more than 120 research projects and product candidates, that comprise nearly half of AstraZeneca's overall R&D portfolio. It is focused on three core therapeutic areas: Oncology; Respiratory, Inflammation and Autoimmune; and Cardiovascular and Metabolic Disease. For further information visit:

https://www.medimmune.com/

 

About Innovate UK

 

Innovate UK is the UK's innovation agency. It works with people, companies and partner organisations to find and drive the science and technology innovations that will grow the UK economy. For further information on the recent announcment visit:

www.innovateuk.gov.uk

or

https://www.gov.uk/government/news/industrial-strategy-boost-for-uk-medicines-with-70-million-of-funding-to-help-develop-new-treatments

 

 

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

MSCSSSFDEFASESE

Close

×

RNS Number : 8305D

Gunsynd PLC

02 February 2018

 

Gunsynd plc

("Gunsynd", or the "Company")

Agreement with FastBase

Gunsynd Plc (AIM: GUN, NEX: GUN) is pleased to announce that it has entered into an agreement with Fastbase, Inc. ("FastBase"), a privately owned Danish SaaS (software as a service) company on the following terms:

In recognition of the efforts made by Gunsynd to assist FastBase in pursuing admission to trading on AIM, it is agreed that FastBase shall pay a consultancy fee of 0.75% of its market capitalization, subject to, and following completion of the IPO.  Such fee is to be paid and settled fully in new ordinary shares of the Company (issued as fully paid ordinary shares, at the Admission price).

About Fastbase, Inc. 

Built upon Google Analytics software, FastBase's software generates comprehensive lead reports that include extensive company profiles, visitor interaction, key employees with LinkedIn profile and email addresses. The insights provided by FastBase enable B2B businesses to contact their online leads in real-time.  

FastBase's popular web leads add-on to Google Analytics is now widely used, including by well-known brands.  It is targeting admission to AIM in Q2, 2018.

Hamish Harris, the Company's Executive Chairman, commented: "We are exceptionally pleased to be able to assist a rapidly growing SaaS company such as FastBase with its plans to list in London.  We will keep investors informed of progress with FastBase's progress in seeking admission to AIM."

 

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

 

The directors of Gunsynd accept responsibility for this announcement.

 

Contacts:-

 

Gunsynd plc:
Hamish Harris		+44 (0) 20 7440 0640
Nominated Adviser / NEX Exchange Corporate Adviser:
Cairn Financial Advisers LLP
James Caithie/Liam Murray		+44 (0) 20 7213 0880
Broker:
Peterhouse Corporate Finance
Lucy Williams		+44 (0) 20 7469 0930

 

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

AGRLLFIRFLIFIIT

Close

×

RNS Number : 2706D

Pennant International Group PLC

30 January 2018

 

 

 

30 January 2018                                   

 

 

Pennant International Group plc: 

CELEBRATING 60 YEARS OF GROWTH AND INNOVATION

1958 – 2018

 

Pennant International Group plc ("Pennant" or the "Group"), the AIM quoted supplier of integrated training and support solutions, products and services, principally to the defence, rail, aerospace and naval sectors and to Government Departments, will be 60 years old on 25 February, 2018.

 

Over the past six decades it has evolved, from modest beginnings, into a market-leading technology-led business with a truly global customer base. It has come a long way since its founder, John Williams commenced developing animated displays using a patented light system, the forerunners of today's sophisticated software training systems. Following on from these beginnings, capabilities were extended to include the manufacture of specially designed scaled models, where early projects included collaboration with Sir Christopher Cockerell to produce prototype designs of the world's first Hovercraft. In 1965, Brian Crawford and David Henderson joined the Company and introduced new technology which opened up the markets of education and training.

 

This resulted in substantial growth for the business, with increased demand for procedural and maintenance trainers for civil and military equipment. The Company continued to expand its technical capabilities, embracing technological advances by taking on larger programmes and producing ever more sophisticated training aids as well as expanding its product offerings still further to include Omega PS LSAR software.

 

The Company's flotation on the London Stock Exchange in March 1998 not only provided much easier access to capital to finance further growth but also a considerably greater public profile which in turn helped to open the doors to a number of  government, defence and international markets and facilitate further significant expansion.

 

Today, the Group is recognised as one of the world's leading suppliers of integrated training and support systems, products and services.

 

Commenting on this major milestone for Pennant and also looking ahead to its continued growth and development, Phil Walker, Group CEO, said:

"I'm proud to be a part of a Company with such a rich heritage and one which has very much moved with the times. Any business is only as good as its people, and I would like to take this opportunity to thank employees past and present for their skills, support and dedication and for making Pennant what it is today, an internationally acknowledged leader in its chosen markets.

 

"Looking to the future, I believe the business is well placed to deliver further growth and innovation, continuing to develop new products and services as we enter the next phase in Pennant's long and distinguished history."   

 

 

 

Enquiries:

 

Pennant International Group plc	www.pennantplc.co.uk
Philip Walker, CEO David Clements, Commercial Director	+44 (0) 1452 714 914 +44 (0) 1452 714 914
WH Ireland Limited	www.whirelandplc.com
Mike Coe / Ed Allsopp	+44 (0) 117 945 3470
Walbrook PR (Financial PR)	[email protected]
Paul Vann / Tom Cooper	+44 (0)20 7933 8780 Mob: +44 (0)7768 807631

     

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

NRAGMGZMFLMGRZZ

Close